Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MegaMOST in Advanced/Metastatic Tumors
NCT04116541Phase 2Recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2020
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of siremadlin, ribociclib, cabozantinib, alectinib, regorafenib in malignant solid tumor, sponsored by Centre Léon Bérard. Started Jan 2020; status: recruiting.
02
Drugs
siremadlinribociclibcabozantinibalectinibregorafenib
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT04116541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116541.